Press Releases
Our latest happenings and recent highlights.
For media inquiries, please contact: daniel.salvo@omniabio.com
Featured
HAMILTON & TORONTO ONTARIO – December 23, 2025 – OmniaBio Inc., Canada’s largest cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), today announced that Health Canada has awarded the company a Drug Establishment License (DEL), confirming the maturity and compliance of its Good Manufacturing Practices (GMP). Secured less than one year after...
Avectas, a cell engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO that enables the development of cell therapies and...
Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver...
OmniaBio, CCRM and Stakeholders Celebrate Commencement of Construction of Hamilton Biomanufacturing Facility...
Next Generation Manufacturing Canada (NGen), the industry-led organization behind Canada’s Global Innovation Cluster for Advanced Manufacturing...
OmniaBio Inc., a subsidiary of CCRM, has executed a strategic agreement with Medipost, a global leader in stem cell therapeutics...
OmniaBio Inc., a subsidiary of CCRM, is the first project to be funded under the Invest Ontario Fund. Subject to reaching a definitive agreement, OmniaBio Inc...